Register Free at
www.chromatographyonline.com/structure
Event Overview:
Monoclonal antibodies (mAbs) represent a fastest growing area, with both innovator mAbs and now biosimilars entering the market. Given the highly complex structure of the mAbs and regulatory requirements, it is important to characterize both the innovator and biosimilar candidate mAbs at various stages of development and production, to retain therapeutic safety and efficacy.
In this study a CESI–MS-MS method was used to perform fast and robust characterization of mAb primary structure and assess biosimilarity between the innovator and biosimiar candidate samples.
Key Learning Objectives:
- Obtain heterogeneity, stability and purity information of mAb from a single enzyme, in a single run.
- Increase workflow efficiency.
- Orthogonal or alternative ESI-MS technology.
Who Should Attend:
Scientists and managers in biopharma R&D or method development whom are involved in characterization of mAbs
|
 |
| Presenters: |
 |
Yannis-Nicolas Francois Ph.D., Associate Professor
Laboratory of Mass Spectrometry of Interactions and Systems University of Strasbourg |
| Moderator: |
 |
Laura Bush
Editorial Director
LCGC |
| Sponsors: |
Presented by:
|
|
|
Sponsored by:
|
 |
| |
|
|
